PPH vs THNR

PPHAVanEck Pharmaceutical ETF

THNRCAmplify Weight Loss Drug & Treatment ETF

In short

PPH About two dozen US-listed drugmakers in one ticker, tracking the MVIS US Listed Pharmaceutical 25 Index since 2011. VanEck charges well under the pharma-fund median to run it.

THNR The GLP-1 trade in one ticker. THNR follows a global index of weight-loss drug developers plus the telehealth and treatment companies the index counts as economic beneficiaries, not just the obvious pharma giants.

Stated mandate

PPH The fund seeks to track, before fees and expenses, the performance of the MVIS US Listed Pharmaceutical 25 Index, which covers companies involved in pharmaceutical research and development, production, marketing, and sales.

THNR The fund provides access to global companies involved in weight-loss drug development or expected to benefit economically from increased use of these treatments, including drug manufacturers and telehealth providers.

Why people hold it

• PPH Costs 0.36% a year against a 0.57% median for pharma ETFs, undercutting peers like PJP and FTXH.
• Focused by design: the index tracks US-listed pharmaceutical companies (research, production, marketing, sales) rather than the whole health care aisle.vaneck.com
• Trading since 2011, one of the veterans of the pharma shelf, and it sits in the top quartile of its peer group on our review.
• Pays out quarterly, and it is a moderately traded fund, so getting in and out is usually straightforward.

• THNR Casts wider than the drugmakers: the mandate covers telehealth providers and other firms tied to rising use of weight-loss treatments.amplifyetfs.com
• Rules-based, not a hunch. It tracks VettaFi's Weight Loss Drug & Treatment Index (THINR), so the lineup changes by published methodology.
• Global by design, so European drugmakers count as much as US ones. Launched in 2024, as GLP-1 treatments moved from niche to headline.

Worth knowing

• PPH Around 26 holdings. One company's trial result or patent cliff carries real weight in a basket this tight.
• Single-sector health care exposure: drug pricing politics and regulation land on the whole basket at once, with nothing else to cushion it.
• The fee edge over the category is real, but XPH sits at 0.35%, so cost alone is not what separates these two.

• THNR The 0.59% expense ratio runs a touch above what global thematic funds typically charge.
• A small fund that trades lightly, so spreads can be wider than on big index funds. Limit orders are the usual tool here.
• One storyline, one drug class. Concentrated by construction, and distributions land annually or semiannually rather than as steady income.

Full PPH profile⁠

Full THNR profile⁠